Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma
Abstract Background High-grade lymphoma in dogs is a chemotherapy-responsive neoplasia with remission rates exceeding 80% under combination chemotherapy protocols. Usually these protocols are intensive and 24 + weeks. The objective of the present study was to investigate if a shorter protocol combin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Acta Veterinaria Scandinavica |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13028-022-00660-z |
| _version_ | 1828264692271808512 |
|---|---|
| author | Stefanie Limmer Verena Nerschbach Nina Eberle Erik Teske Daniela Simon Betz |
| author_facet | Stefanie Limmer Verena Nerschbach Nina Eberle Erik Teske Daniela Simon Betz |
| author_sort | Stefanie Limmer |
| collection | DOAJ |
| description | Abstract Background High-grade lymphoma in dogs is a chemotherapy-responsive neoplasia with remission rates exceeding 80% under combination chemotherapy protocols. Usually these protocols are intensive and 24 + weeks. The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice. Results 144 dogs entered the study. Lymphoma types included multicentric (n = 123), alimentary (n = 13), miscellaneous (n = 7), and mediastinal lymphoma (n = 1). Overall response rate was 83.3% (B-cell: 86.6%, T-cell: 79.4%). Complete remission (CR) was achieved in 72.2% (B-cell: 77.3%, T-cell: 67.6%) and partial remission (PR) in 11.1% (B-cell: 9.3%, T-cell: 11.8%) of the dogs. Median duration of first CR amounted to 242 days (B-cell: 263 d, T-cell: 161 d). Median survival in dogs with CR was 374 days (B-cell: 436 d, T-cell: 252 d), and median overall survival time was 291 days (B-cell: 357d, T-cell: 210d). Immunophenotype demonstrated an independent significant influence on duration of remission and survival in the whole group. Findings of splenic and hepatic cytology were not significant associated with patient outcome. Treatment was well tolerated; the majority of adverse events were classified as grade 1 or 2. Conclusions Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma. |
| first_indexed | 2024-04-13T04:29:38Z |
| format | Article |
| id | doaj.art-737f5772faed4348bb197ebbfb3ac569 |
| institution | Directory Open Access Journal |
| issn | 1751-0147 |
| language | English |
| last_indexed | 2024-04-13T04:29:38Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Acta Veterinaria Scandinavica |
| spelling | doaj.art-737f5772faed4348bb197ebbfb3ac5692022-12-22T03:02:23ZengBMCActa Veterinaria Scandinavica1751-01472022-12-0164111210.1186/s13028-022-00660-zEfficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphomaStefanie Limmer0Verena Nerschbach1Nina Eberle2Erik Teske3Daniela Simon Betz4Small Animal Hospital, University of Veterinary Medicine HannoverSmall Animal Hospital, University of Veterinary Medicine HannoverCenter for Small Animal Medicine, VetSpezialDepartment of Clinical Sciences, Veterinary Faculty, Utrecht UniversitySmall Animal Hospital, University of Veterinary Medicine HannoverAbstract Background High-grade lymphoma in dogs is a chemotherapy-responsive neoplasia with remission rates exceeding 80% under combination chemotherapy protocols. Usually these protocols are intensive and 24 + weeks. The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice. Results 144 dogs entered the study. Lymphoma types included multicentric (n = 123), alimentary (n = 13), miscellaneous (n = 7), and mediastinal lymphoma (n = 1). Overall response rate was 83.3% (B-cell: 86.6%, T-cell: 79.4%). Complete remission (CR) was achieved in 72.2% (B-cell: 77.3%, T-cell: 67.6%) and partial remission (PR) in 11.1% (B-cell: 9.3%, T-cell: 11.8%) of the dogs. Median duration of first CR amounted to 242 days (B-cell: 263 d, T-cell: 161 d). Median survival in dogs with CR was 374 days (B-cell: 436 d, T-cell: 252 d), and median overall survival time was 291 days (B-cell: 357d, T-cell: 210d). Immunophenotype demonstrated an independent significant influence on duration of remission and survival in the whole group. Findings of splenic and hepatic cytology were not significant associated with patient outcome. Treatment was well tolerated; the majority of adverse events were classified as grade 1 or 2. Conclusions Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma.https://doi.org/10.1186/s13028-022-00660-zDogPrognostic factorsRemissionShort-term chemotherapySurvival |
| spellingShingle | Stefanie Limmer Verena Nerschbach Nina Eberle Erik Teske Daniela Simon Betz Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma Acta Veterinaria Scandinavica Dog Prognostic factors Remission Short-term chemotherapy Survival |
| title | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma |
| title_full | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma |
| title_fullStr | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma |
| title_full_unstemmed | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma |
| title_short | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma |
| title_sort | efficacy and tolerability of a 12 week combination chemotherapy followed by lomustine consolidation treatment in canine b and t cell lymphoma |
| topic | Dog Prognostic factors Remission Short-term chemotherapy Survival |
| url | https://doi.org/10.1186/s13028-022-00660-z |
| work_keys_str_mv | AT stefanielimmer efficacyandtolerabilityofa12weekcombinationchemotherapyfollowedbylomustineconsolidationtreatmentincaninebandtcelllymphoma AT verenanerschbach efficacyandtolerabilityofa12weekcombinationchemotherapyfollowedbylomustineconsolidationtreatmentincaninebandtcelllymphoma AT ninaeberle efficacyandtolerabilityofa12weekcombinationchemotherapyfollowedbylomustineconsolidationtreatmentincaninebandtcelllymphoma AT erikteske efficacyandtolerabilityofa12weekcombinationchemotherapyfollowedbylomustineconsolidationtreatmentincaninebandtcelllymphoma AT danielasimonbetz efficacyandtolerabilityofa12weekcombinationchemotherapyfollowedbylomustineconsolidationtreatmentincaninebandtcelllymphoma |